COMPANY UPDATE. 2019 - VOLITIONRX
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Company Update. 2019
Volition • Update 2019 2 3
Volition • Update 2019
A few words
from our
Executive Chairman
Our mission is simple: to save lives by revolutionizing the way
disease, and especially cancer, is diagnosed. To this end, Volition
is developing simple, easy to use blood-based tests to diagnose
a range of cancers and other diseases.
Cancer is the second leading We believe that there is a high
cause of death and is responsible unmet clinical need for veterinary
I am really proud to for 1-in-6 deaths worldwide each
year. It’s a disease that touches
diagnostics and given the
generally quicker USDA regulatory
be Executive Chairman
and affects so many of our lives. pathway to approval for veterinary
It is widely accepted that the products as compared to FDA
best way of tackling cancer is approval for human products,
of Volition and am for patients to receive an early
diagnosis, as this improves their
chances of surviving cancer.
Volition intends to develop
products for this market as soon
as possible which could provide
delighted with the I am delighted with the progress
early revenue for the company.
we have made in 2018 in the As our research develops, we
progress the Company development of new tests
using our technology platform
are continuously growing our
intellectual property portfolio
has made since its of Nucleosomics™, which is
the practice of identifying and
measuring nucleosomes in the
which provides broad coverage
(including animal use) that we
believe will help protect our long-
inception in 2011. bloodstream or other bodily fluid.
I am also excited by the data that
term competitive advantage.
we expect to report throughout Finally, I would like to thank the
2019 and beyond across such a many collaborators we work with
broad range of cancers including: around the world and the Principal
lung, colorectal, prostate, Investigators of our many clinical
pancreatic, ovarian, and head trials. I’d also like to acknowledge
and neck, as well as other diseases the contribution and continued
such as endometriosis. support from the members of our
Scientific Advisory Board and the
Our research and development continued financial support of the
program during 2018 included Walloon Region of Belgium. I look
some interesting proof of concept forward to announcing the results
work in the veterinary field, of key studies in this coming year.
including dogs and horses.
Dill Faulkes
Dill Faulkes
Executive Chairman
4 5
Volition • Update 2019
A few words from our
I am incredibly
Chief Executive Officer proud of the team
I am absolutely delighted with the progress we
have made on so many fronts in 2018, particularly we have assembled;
with the work on the basics of our Nu.Q™ platform.
individuals who come
I am very happy to report the This development work will be
initial data from this work, and
we expect to be able to report a
key to our future success and our
initial assays have now completed
to work every day
large volume of data throughout
2019 and beyond with our newly
optimized assays and matrixes.
this extremely vigorous process.
This work has gone very well with
our growing team at our large
to create a brighter
We have a strong financial position
lab in Belgium. However, it is fair
to say the development work future, one where
which we believe, given the cost on the robustness of our assays
effectiveness of our research and
development program, provides a
has proven to be a massive and
time-consuming undertaking.
hope and cancer can
come together in the
great runway to achieve our many Given that we are the first group
milestones in 2019 and beyond. to have worked in the field of
Nucleosomics, much work has
I am delighted that our worldwide
portfolio of granted patents that
had to be started from scratch.
same sentence.
protect various aspects of Volition’s I am delighted this report includes
Nu.Q technology continues to grow. the initial results in three separate
This is a key differentiator versus small cohorts with the first
many other technologies either completed Nu.Q assay and one
Chief Executive Officer
under development or available iNu.Q assay. In a lung cancer cohort
on the market, where the patent (76 subjects), a single Nu.Q assay
position maybe poor and/or narrow. detected lung cancer, including
stage I lung cancer. In this initial
From a research and development cohort, we achieved our best ever
point of view, 2018 was a very busy single-assay detection result with
year; however, it was fairly quiet an AUC of 85% (lung cancer vs
in terms of press announcements, healthy), the performance of which
as we very much focused on was further improved when used
platform development. Our team in combination with a two-assay
is delighted with the significant panel. In a second confirmatory
Cameron
progress that has been made in lung cancer cohort (152 subjects)
2018. I would like to thank our the same Nu.Q assay also detected
research and development team, lung cancer with an AUC of 79%.
for their tireless and tenacious
efforts throughout the year. The vast This initial proof of concept data
majority of this work was focused gave us confidence to move onto
on advancing the development of larger lung cancer studies and
our clinical assays to the analytical I’m delighted to have extended
validity needed for large clinical our collaboration with the National
grade trials, and for products, Taiwan University to embark upon
as well as extending the use a 1,200 subject lung cancer study
of our Nu.Q assays on a range in the second quarter of 2019.
of platforms.
6 7
Volition • Update 2019
Our new lab has enabled expansion of
research and development programs from
Nu.Q diagnostic tests to now include
Nu.Q Vet and Nu.Q Capture.
In the fourth quarter of 2018, From a commercial point of view, The Nu.Q Capture project, And so, to future milestones. We are grateful through our
it was exciting to learn that not we are extremely excited about leverages the work we have been As many of you know, we have on-going trial program to
only could our Nu.Q technology the opportunity to offer Nu.Q doing to investigate the use of concentrated our research efforts be working with renowned
help save lives and improve the Vet tests to animal owners and Nucleosomics to purify or enrich to date on colorectal cancer – collaborators around the world,
quality of life for man-kind, but veterinarians. There are currently tumor associated nucleosomes. which is the most preventable and all of whom have outstanding
we are hopeful our technology no accurate, simple, affordable I am delighted to be able to yet currently least prevented form reputations and share our aim
will also be effective in helping cancer screening or diagnostic announce that with Nu.Q Capture of cancer and we very much look in improving early diagnosis
diagnose a range of diseases tests available in veterinary we have been able to deplete/ forward to completing our large- of cancer.
in animals. medicine and yet 25% of dogs will enrich nucleosomes by 70-90% scale clinical studies throughout
develop cancer at some stage of using magnetic beads in serum 2019/2020. We believe that Nu.Q will provide
Following the completion of their life. We believe that this is a and plasma. The next step a low-cost routine blood test
several small-scale studies in dogs, multi-billion-dollar opportunity is to determine the level of In addition to our colorectal cancer allowing doctors to check off an
our subsidiary Volition America and we aim to have the first Nu.Q discrimination of tumor associated studies, we are hopeful that our extra box along with other routine
Inc. is now conducting a study Vet product on the market in 2020. nucleosomes using mass recent proof of concept results blood tests, such as cholesterol
of our Nu.Q Vet assays in cancer spectrometry and/or sequencing. in lung cancer will be repeated and PSA, during a single visit,
and other diseases in cooperation Our research and development in much larger cohorts, and and that this is currently the only
with Texas A&M University’s team has grown significantly since This potential breakthrough with additional assays currently credible way of taking compliance
College of Veterinary Medicine, we moved into our larger, purpose- product aims to enrich tumor in development. Lung cancer with screening above 80%.
a leading U.S. veterinary institution. built laboratory in Belgium in 2017. associated DNA which in turn will remains the deadliest of all the
The U.S. is currently the largest This has enabled expansion of help address the main technology cancers and we believe that there We are extremely proud of
veterinary market in the world and our research and development barrier to DNA cancer diagnostics. is a high unmet clinical need for the accomplishments we have
has a clearly defined regulatory programs from our Nu.Q either a non-invasive early stage achieved thus far and look forward
pathway via the USDA, requiring diagnostic tests to now include not Nu.Q Capture is platform agnostic lung cancer detection test and/ to what the future holds for Volition.
fewer and smaller clinical studies only Nu.Q Vet as described above, with the ultimate aim of providing or for a test which can improve the I, along with the rest of the Board,
than the FDA process for human but also Nu.Q Capture. complete nucleosome analysis specificity of the Low-Dose CT scan and indeed the whole company,
diagnostics. This generally allows and origin of cancer. This is still currently used in many markets. look forward to sharing the results
a much faster route to revenue for very much a work in progress, but of key studies over the coming
veterinary products as compared we have made significant progress We aim with our solid cash year with our optimized platform.
to human products, given trials this past year, and our team is position, to report throughout
need to be in the hundreds, not very excited about this potential 2019 and beyond Nu.Q’s ability to We work hard every day to create
thousands of subject-samples. addition to our platform. detect a range of cancers including a brighter future, one where hope
lung, colorectal, prostate, and cancer can come together in
pancreatic, ovarian, head and the same sentence.
neck in addition to our 27-cancer
study, and other conditions such
as endometriosis as well as data
from both the Nu.Q Vet and
Nu.Q Capture programs.
8 9
Volition • Update 2019
We closed 2018 with $13.4 million cash and cash equivalents
compared to $10.1 million as of the end of 2017.
In the first quarter of 2018, we proceeds from the exercise of of our collaborations with leading
raised $8.4 million in aggregate warrants). During 2018, existing institutions. Consequently, we
gross proceed through an investors also exercised warrants continue to manage cash carefully
The whole team
underwritten public offering of to purchase common stock that and had a steady cash burn rate
common stock with Oppenheimer resulted in approximately $717,000 of approximately $3.9 million per
& Co. Inc. acting as the sole in aggregate net proceeds. quarter during 2018.
book-running manager and
National Securities Corporation
acting as a co-manager in
We have also continued to attract
non-dilutive funding, especially
In the first quarter of 2019, over
$6.7 million in aggregate gross
is committed and
connection with the offering.
Our cash position was further
from the Walloon region, Belgium,
which has provided over $3.7 million
proceeds has been received
from the exercise of warrants to passionate about
strengthened in 2018 with a in funds to-date. purchase common stock, which
private placement (PIPE) of
common stock and warrants Our research and development
demonstrated continued support
from our dedicated investors
the work we do.
to an existing shareholder program is remarkably cost and further strengthens our
for aggregate gross proceeds effective, especially given the size cash position.
of $9 million (excluding any of the trials and the nature
David
Chief Financial Officer
Rod
Corporate Secretary
Our worldwide portfolio of granted patents
that protects various aspects of Volition’s Nu.Q
technology is growing.
It is great to be We have 20 patent families property portfolio to gain market
working with a skilled related to our diagnostic tests,
with 7 patents granted in the
United States and 7 patents
exclusivity in Europe, the United
States and in other strategic
countries. The patents on the
and passionate team granted in the European Union
and a further 25 patents granted
technologies underlying our
products should provide broad
worldwide. Additionally, we have coverage for each product,
focused on saving 106 patent applications pending
worldwide. This portfolio also
including protection through at
least 2031 for products developed
lives and reducing covers veterinary medicine
applications.
using the Nu.Q technologies.
We have signed multiple contracts
the cost of cancer to We intend to continue our
development of the Nucleosomics
throughout 2018 with our growing
team of collaborators and look
technologies and to apply for forward to adding even more to
healthcare systems patents identified through such
efforts. Our strategy is to protect
the list in 2019.
around the world.
our technologies and leverage
the strength of our intellectual
10 11
Volition • Update 2019
Using our Nu.Q technology,
we aim to make cancer diagnosis
as accessible as cholesterol or
pregnancy testing.
The principle behind and/or low-cost ELISA tests in our How is Nu.Q different from ctDNA?
panels (e.g. CEA, PSA, CA125) for
what we are doing higher accuracy. • When a cancer cell dies
relies on bringing the nuclear components are
Many companies and medical metabolized into 20 million
together two main lines schools are developing circulating individual DNA-Nu complexes
of research and is, in tumor DNA or ctDNA tests based and released into circulation.
on sequencing the DNA attached A cancer mutation will occur in
concept, very simple: to these nucleosomes. Volition’s one of the DNA-Nu complexes.
diagnostic target in the blood
The chromosomes of cancer cells
is the same tumor chromosome • ctDNA sequencing methods
differ from those of healthy cells –
fragment, but our approach is (in development) must target
both in terms of DNA sequence
to test for chromosome protein that one-in-a-million DNA-Nu
(due to genetic cancer mutations)
and nucleic acid changes in intact complex.
and in protein structure – due to
chromosome fragments by ELISA,
epigenetic changes.
rather than chemically extracting, • Nu.Q targets ALL 20 million
amplifying, and sequencing the circulating DNA-Nu complexes
There are chromosome fragments
ctDNA and discarding the rest because nucleosome
Chief Scientific Officer
from dead cancer cells circulating
of the nucleosome. ELISA is modifications occur globally.
in the blood as nucleosomes.
possible because the targets of
Each such circulating nucleosome
our tests occur globally across • Nu.Q is a simple, low-cost
contains a small (approximately
all nucleosomes within a tumor ELISA and can incorporate other
140 base pairs) fragment of
cell, whereas individual ctDNA ELISA tests in Volition’s panels.
tumor DNA.
changes must be identified
within the three billion base- There are multiple phases to the
Volition’s Nucleosomics
pair genomes. This means that Product Development process, and
technology exploits the different
the targets of our tests are we are delighted in 2018 to have
compositions of circulating
exponentially more prevalent in made the significant step forward
nucleosome structures present
circulating blood, and detectable in developing some of our Nu.Q
in the blood of cancer patients
using simple laboratory methods. assays to product grade status
to detect and identify cancer
(by which we mean analytically
diseases.
validated and of clinical grade,
so that they can be reproducible
We are developing a novel suite
Jake
anywhere, in any laboratory), so
of blood assays of epigenetically
that clinical trials may commence.
altered circulating nucleosomes
as biomarkers in cancer and other
diseases. Nu.Q products aim to
be simple, low-cost, enzyme-
linked immunosorbent assay
(“ELISA”) platform tests and can
incorporate other biomarkers
such as anti-inflammatory markers
12 13
Volition • Update 2019
How it works Each individual
protein/DNA
The genome is
“bead” is called a
3 billion base pairs.
nucleosome.
If uncoiled it would measure
5 feet long. Every 140 base
pairs of DNA are wrapped Nucleosomes consist
around a nucleosome to of DNA and histone
form a DNA-Nu complex. proteins. Histones and
DNA are subjected to
Chromosome a variety of epigenetic Cancer leads to cell
DNA strand modifications.
death which results in
fragmentation
and release
of nucleosomes
into the blood.
Our Nucleosomics
DNA wrapped around histones
technology exploits
the different compositions
of circulating nucleosome
The DNA in every structures present in the
cell is wound serum of cancer patients to
detect and identify
around protein
complexes in a
“beads on a cancer diseases.
string” structure.
14 15
Volition • Update 2019
The global cancer market: 2018
Globocan Project, Ferlay et al.
Lung Breast Colorectal Prostate Stomach
Diagnoses Diagnoses
Diagnoses Diagnoses Diagnoses
Deaths
2.1m 2.1m 881k 1.8m 1.3m 1m
Deaths Deaths
359k 783k
Deaths
627k Deaths
Deaths in Asia
1.8m 584k
There were 18.1 million cancer diagnoses
worldwide in 2018 with a resulting mortality burden
of almost 10 million people. Given the growing
and more importantly aging population, cancer’s
burden is expected to worsen.
By 2040 it is predicted that there will be 29.5 million
new cases of cancer diagnosed each year and
over 16 million cancer-related deaths.
16 17
Volition • Update 2019
Product Strategy.
We anticipate that we will develop multiple
Nu.Q products across the whole range of
cancers falling into the following categories:
We work hard
every day to help Frontline High Risk
Frontline Disease Treatment
General Population Screening Monitoring Selection
change people’s Screening Tests ‘Triage’ Tests
Diagnostic
Tests Tests Tests
lives throughout For To work in To aid the To help A personalized
the world. asymptomatic
subjects for the
conjunction
with existing
diagnosis of
disease in
monitor high
risk groups
medicine
approach to
most prevalent tests to improve symptomatic and/or identify help identify
cancers. sensitivity and/ patients. the recurrence the most
or specificity. of a disease. appropriate
treatment for
the individual.
Cancers currently being researched with product grade assays include:
Proof of Concept Training Validation
Lung 2019 2020
Colorectal 2019 2020
Prostate 2020 2021
Pancreatic 2019 2020 tbc
Ovarian 2019 2020 tbc
Lou
Head & Neck 2019 tbc tbc
Chief Marketing & Gastric 2019 tbc tbc
Communications Officer 27 Most Prevalent Cancers 2019
18 1920
The Volition Laboratory
Belgium
Volition • Update 2019
21Volition • Update 2019
Product grade assays -
Proof of concept data In a small lung cancer
cohort (N=76) the same single
Nu.Q assay detected Lung cancer
including stage I lung cancer.
In a small The AUC for this single
multi-cancer cohort Nu.Q assay was 85%.
(N=50) a single Nu.Q
assay detected This performance was
Lung Prostate and further improved when
used in combination
Colorectal cancer. within a 2-assay panel.
In the same cohort
a 2-assay panel detected
In a second lung
all stages of colorectal
cancer including stage I
and had an AUC of 85%. cancer cohort (N=152) the
In a small colorectal same Nu.Q assay detected
cancer cohort (N=123) Lung cancer. The AUC
a single Nu.Q assay detected
Again, this for this single Nu.Q
Colorectal cancer with an performance was assay was 79%.
with an AUC of 72%. further improved
when used in a
two-assay panel.
22 23Volition • Update 2019
The programs we
have launched
A focus on Asia with collaborators
worldwide speak
We are delighted with the well of the belief
progress we have achieved with they have in our
the network of key influencers technology
and potential collaborators in Asia. and our team.
We have expanded Our large-scale colorectal We have made significant We are getting
cancer studies are well progress with our entrance into
our relationship with
the National Taiwan
underway with National Taiwan
University. The first trial, a multi-
China with a collaboration with
Shanghai Fosun Long March (an
closer in realising
University. center study will include 5,000
asymptomatic screening subjects
to evaluate the performance of
IVD company wholly owned by
Fosun Pharmaceutical Group
Co Ltd, a leading healthcare
our vision to
develop an effective
In addition to the large colorectal our Nu.Q Frontline Asymptomatic company in China).
cancer studies, we have recently Colorectal Cancer Screening
announced a prospective lung Test. The second study includes With Fosun Long March, we
cancer study involving 1,200
subjects. Lung cancer remains
the deadliest of all the cancers
2,000-symptomatic patients
and will be used to evaluate
plan to conduct three clinical
studies on colorectal, lung
platform to detect
cancers early.
the performance of our Nu.Q and ovarian cancers in China.
and we believe that there is a high colorectal cancer symptomatic In addition, we are jointly
unmet clinical need for a non- test. Professor Han-Mo Chiu and exploring the development
invasive early stage lung cancer his team are collecting well ahead of Nu.Q assays utilizing
detection and/or for a test which of schedule and we look forward their LUMIART-II Automated
can improve the specificity of to reporting some preliminary Chemiluminescence
the low-dose CT scan currently results in 2019. Immunoassay System.
used in many markets. We are
hopeful that our recent proof We are excited that our work in
of concept results in lung cancer China will be underway in 2019
will be repeated in this much and look forward to a successful
larger cohort. collaboration with Fosun
Long March.
Jasmine
Chief Executive Officer,
Singapore Volition
24 25Volition • Update 2019
It’s exciting that not only could our Nu.Q
technology help save lives and improve the
quality of life for man-kind, but we are hopeful
our technology will be effective in helping
diagnose a range of diseases in animals.
In the fourth quarter of 2018, than the FDA process for human
we were delighted to present diagnostics. This generally allows
some very encouraging preliminary a much faster route to revenue for
results from a proof of concept veterinary products as compared
Chief Medical Officer & Chief Executive
study using our Nu.Q diagnostics to human products.
platform in veterinary medicine.
From a commercial point of view,
The proof of concept study we are extremely excited about
demonstrated that nucleosomes the opportunity to offer Nu.Q
can be detected in dogs and Vet tests to animal owners and
therefore, have the potential to veterinarians. There are currently
differentiate cancer from other no accurate, simple, affordable
Officer of Volition America Inc.
conditions in canines. Following cancer screening or diagnostic tests
the completion of several available in veterinary medicine
small-scale studies in dogs, our and yet 25% of dogs will develop
subsidiary Volition America Inc. is
now conducting a study in cancer
cancer at some stage of their life.
Cancer doesn’t
discriminate –
and other diseases in collaboration Volition’s extensive intellectual
with a Texas A&M University’s property portfolio includes
College of Veterinary Medicine, a coverage of veterinary
leading U.S. veterinary institution.
We hope that this study will
applications. We believe that
licensing this technology could it causes fear, pain
advance our plans to partner with potentially provide significant
academic and industry leaders to
expedite regulatory approval and
revenue for Volition, in addition
to providing further technical
and suffering for all
product commercialization.
The U.S. is currently the largest
validation of our platform.
those it touches.
veterinary market in the world and
has a clearly defined regulatory Early diagnosis is a
critical component
pathway via the USDA, requiring
fewer and smaller clinical studies
Jason
of curing cancer.
26 27Volition • Update 2019
It is tremendously
rewarding working on such
a cutting-edge technology
- one that has the potential
to not only help diagnose
cancer, but also potentially
many other conditions.
We were delighted to sign a global license,
manufacturing, sales and distribution
agreement with Active Motif for a range
Business Development Director
of Research Use Only kits. Based on our
proprietary Nucleosomics technology,
the kits are expected to:
• Allow researchers to explore patterns
of epigenetic modifications in circulating
nucleosomes across a broad range of
clinical applications including cancers,
inflammatory and infectious diseases; and
• Represent the first revenue from the
Nu.Q platform and potentially provide
an additional licensing revenue stream
beyond the commercialization of our
blood-based cancer tests utilizing the
same platform of assays.
The first kit was launched in the second half
of 2018 and we look forward to expanding
Mark
the range of available kits throughout 2019
and beyond.
In addition to the RUO Kit development we
have also done a lot of broader work on our
platform including adapting our assays for
magnetic beads and chemiluminescence,
both very important breakthroughs which
could make our platform much more
adaptable and robust.
28 29Volition • Update 2019
Our research and development team has grown significantly since we moved
into our larger, purpose-built laboratory in Belgium, in 2017. This has enabled
expansion of our research and development programs from our Nu.Q
diagnostic tests to now include not only Nu.Q Vet but also Nu.Q Capture.
The Nu.Q Capture project The next step is to determine barrier to DNA cancer diagnostics.
leverages the work we have been the level of discrimination of Nu.Q Capture is platform agnostic
doing to investigate the use of tumor associated nucleosomes with the ultimate aim of providing
Nucleosomics to purify or enrich using mass spectrometry and/ complete nucleosome analysis
tumor associated nucleosomes. or sequencing. and origin of cancer.
Thus far with Nu.Q Capture we
have been able to deplete/enrich This potential breakthrough
nucleosomes by 70-90% using product aims to enrich tumor
magnetics beads in serum associated DNA which in turn will
and plasma. help address the main technology
Depletion/Enrichment
The team thrives
on the desire to Nu.Q™ Nu.Q™ Nu.Q™
change the outlook Mass Spec Seq Immunoassay
for cancer patients
throughout the world.
Complete
Nucleosome
Analysis
Gaetan
Commercial concept
Chief Executive Officer
of Belgian Volition SPRL Complete Nucleosome analysis.
30 31Volition • Update 2019
The Volition Biobank
Institution Condition Sample Collection Cohort Timing
Proof of Concept
Early Detection Research 9,000 Prospective, 13,500 + Ongoing to 2020
Colorectal
Network of the U.S. 4,600 Retrospective Screening
National Cancer Institute Population
Condition Sample Cohort Expected Data Release
National Taiwan Prospective 5,000 Ongoing to 2021
Colorectal
University Asymptomatic Colorectal N = 225 Q2 2019
Population
Colorectal N = 552 H1 2019
National Taiwan Prospective 2,000 Ongoing to 2021
Colorectal
University Symptomatic
Patients
Colorectal N = 352 H2 2019
Hvidovre Hospital, Prospective 14,000 Collection
Colorectal N = 76 Q1 2019
University of Screening completed and Lung
Copenhagen Population analysis ongoing
Lung N = 152 H1 2019
Hvidovre Hospital, Colorectal Prospective 30,000 Collection
University of Screening completed and
Copenhagen Population analysis ongoing
Prostate N = 120 H1 2019
Hvidovre Hospital, Colorectal Retrospective 4,800 Collection
University of Symptomatic completed and N = 100 H2 2019
Prostate
Copenhagen Patients analysis ongoing
N = 100 H2 2019
National Taiwan Prospective 1,200 Subjects Expected to Pancreatic
Lung
University start mid-2019
to 2021
Head & Neck N = 200 H2 2019
German Cancer Retrospective 750 Subjects Collection
Research Center (DKFZ) Pancreatic completed Endometriosis N = 10 H2 2019
and analysis (x 5 collections)
ongoing
University of Bonn 27 Most Prospective 4,500 Subjects Collection Endometriosis N = 300 H2 2019
Prevalent Cancers completed and
analysis ongoing
32 33Volition • Update 2019
Volition is very fortunate to have attracted
numerous long-term shareholders to our
Company who share the same vision of
revolutionizing cancer diagnostics, helping
people find cancer earlier, and improving
outcomes for millions of people worldwide.
Executive Vice President
We have a very active investor
relations program, attending
numerous investor-focused
conferences annually, and
Investor Relations
conducting investor presentations
in major financial centers across
the United States and Europe on a
regular basis. Our goal is to raise the
awareness of Volition and its mission
in order to broaden the investor
base and ultimately to maximize
shareholder value.
For any further information please
Scott
contact investorrelations@volitionrx.com
It is such a pleasure to be
involved with a company that
has the potential to do so much
good for humanity while providing
potential upside to shareholders.
34 35Volition • Update 2019
Investor information.
Annual Meeting: Friday June 14, 2019
Board of Directors
Cameron Reynolds, President & Chief Executive Officer
Dr Martin C Faulkes, Executive Chairman
Guy Innes ACA, Non-Executive Director
Dr Alan Colman, Non-Executive Director
Dr Edward Futcher, Non-Executive Director
Dr Habib Skaff, Non-Executive Director
Transfer Agent
V Stock Transfer, LLC
18 Lafayette Place,
Woodmere NY 11598
Tel: 212-828-8436
Fax: 646-536-3179
info@vstocktransfer.com
www.vstocktransfer.com
Unless stated otherwise, the statements in this Brochure are made as of 9th April
2019. Information contained in this Brochure concerning the industry and markets
in which VolitionRx and its subsidiaries operate is based on information from
independent industry and research organizations, other third-party sources and
management estimates. Management estimates are derived from publicly available
information released by independent industry analysts and third-party sources, as
well as data from VolitionRx’s internal research, and are based on assumptions made
by management upon reviewing such data and its knowledge of such industry and
markets which it believes to be reasonable. Although VolitionRx believes the data
from these third-party sources is reliable, it has not independently verified any third-
party information.
Additionally, this Brochure contains forward-looking statements regarding future
events and the future performance of VolitionRx and its subsidiaries that involve
risks and uncertainties that could cause actual results to differ materially from those
contemplated by the forward-looking statements. Risks that could cause results to
differ include those described in the section entitled “Risk Factors” in VolitionRx’s
Form 10-K as well as risks described in further detail in the Company’s other
documents filed from time to time with the Securities and Exchange Commission,
copies of which can be accessed electronically at www.sec.gov. Further, actual
results may differ as a result of additional risks and uncertainties of which VolitionRx
is currently unaware or which management does not currently view as material to
the business. Any forward-looking statements contained in this Brochure reflect
only the current views of VolitionRx with respect to such matters and are made
subject to applicable risks, uncertainties and assumptions. As a result, there can be
no assurance that the events or other matters described in such forward-looking
statements will, in fact, transpire and readers are cautioned not to place undue
reliance on any forward-looking statements. VolitionRx does not undertake any
obligation to update such forward-looking statements. No representation or
warranty, express or implied, is made as to the completeness or accuracy of the
information contained herein.
For more information visit www.volitionrx.com
Nucleosomics™ and Nu.Q™ and their respective logos are trademarks and/or
service marks of VolitionRx and its subsidiaries. Additionally, all references to “$”
in this Brochure refer to the legal currency of the United States of America.
36 37Volition • Update 2019 38 39
You can also read
